Revenue recognition and accounts receivable (Tables)

3 Months Ended

Mar. 31, 2023

Revenue Recognition And Accounts Receivable [Abstract]

Schedule of Net Sales by Major Product Category by Reporting Segment

The table below presents net sales by major product category by reporting segment:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2023		2022		Change
Bone Growth Therapies	$	47,714	$	41,948		13.7	%
Spinal Implants and Enabling Technologies		60,862		26,615		128.7	%
Biologics		40,630		14,092		188.3	%
Global Spine		149,206		82,655		80.5	%
Global Orthopedics		25,998		23,763		9.4	%
Net sales	$	175,204	$	106,418		64.6	%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2023		2022
Product sales	$	162,248	$	92,608
Marketing service fees		12,956		13,810
Net sales	$	175,204	$	106,418

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three months ended March 31, 2023 and 2022:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2023			2022
Allowance for expected credit losses beginning balance	$	6,419		$	4,944
Addition resulting from the Merger with SeaSpine		137			-
Current period provision for expected credit losses		208			600
Write-offs charged against the allowance and other		(126	)		(104	)
Effect of changes in foreign exchange rates		53			(51	)
Allowance for expected credit losses ending balance	$	6,691		$	5,389